Bristol-Myers Squibb Company
BMY (NYSE)
Bristol Myers Squibb offers an attractive dividend yield of 4.19% despite a challenging 5-year return of -10.87%. Recent performance shows a strong 21.32% return over the past year, and analysts maintain a positive outlook with a median 12-month price target of $60.00, supported by multiple "Buy" ratings. However, the company faces ongoing pressures from its legacy drug portfolio, which could impact future growth.
Pros:
- Strong pipeline of pharmaceutical products
- Consistent dividend payments
Cons:
- Challenges in legacy drug sales
- Competition from generics
Bristol-Myers Squibb may appeal to income-focused investors seeking a robust dividend yield of 4.19%, particularly those willing to navigate potential volatility stemming from its legacy drug portfolio. While the recent 21.32% return over the past year is promising, prospective investors should weigh this against the company's challenging 5-year performance and consider their risk tolerance regarding future growth potential.